克服多重耐药肺炎克雷伯菌感染。

IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES
Nastaran Javan, Reza Ghotaslou, Hossein Samadi Kafil, Mohammad Yousef Memar, Javid Sadeghi, Pardis Ghotaslou
{"title":"克服多重耐药肺炎克雷伯菌感染。","authors":"Nastaran Javan, Reza Ghotaslou, Hossein Samadi Kafil, Mohammad Yousef Memar, Javid Sadeghi, Pardis Ghotaslou","doi":"10.1177/10766294251375937","DOIUrl":null,"url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) is one of the most important concerns in the world, occurring for both Gram-positive and Gram-negative bacteria. <i>Klebsiella pneumoniae</i> (<i>K. pneumoniae</i>) is a Gram-negative bacterium belonging to the family of Enterobacteriaceae and also plays an important role in development of nosocomial infections. Three forms have emerged as a result of AMR including multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant. Nowadays, physicians cannot save most of the patients that suffer from MDR <i>K. pneumoniae</i> infections by typical antibiotics, so they should try other useful alternative treatments. Our aim in this review study was to search about the latest useful alternative methods against MDR <i>K. pneumoniae</i> infections. We collected some articles from PubMed, MEDLINE, and Google Scholar by the keywords of multi-drug-resistant <i>K. pneumoniae</i>, AMR, and alternative treatments, where finally 183 articles were selected. Also, inclusion criteria and exclusion criteria were identified separately. It was understood that there are novel therapeutic options against MDR <i>K. pneumoniae</i> infections, which include odilorhabdins, drug delivery systems, antibody drug conjugation treatments, nano-antibiotics, bacteriocins, probiotics, fecal transplant therapy, predatory bacteria, combined antibiotics, double-carbapenem therapy, synthetic lipopeptides, and phage therapy.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overcoming Multi-Drug-Resistant <i>Klebsiella pneumoniae</i> Infections.\",\"authors\":\"Nastaran Javan, Reza Ghotaslou, Hossein Samadi Kafil, Mohammad Yousef Memar, Javid Sadeghi, Pardis Ghotaslou\",\"doi\":\"10.1177/10766294251375937\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Antimicrobial resistance (AMR) is one of the most important concerns in the world, occurring for both Gram-positive and Gram-negative bacteria. <i>Klebsiella pneumoniae</i> (<i>K. pneumoniae</i>) is a Gram-negative bacterium belonging to the family of Enterobacteriaceae and also plays an important role in development of nosocomial infections. Three forms have emerged as a result of AMR including multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant. Nowadays, physicians cannot save most of the patients that suffer from MDR <i>K. pneumoniae</i> infections by typical antibiotics, so they should try other useful alternative treatments. Our aim in this review study was to search about the latest useful alternative methods against MDR <i>K. pneumoniae</i> infections. We collected some articles from PubMed, MEDLINE, and Google Scholar by the keywords of multi-drug-resistant <i>K. pneumoniae</i>, AMR, and alternative treatments, where finally 183 articles were selected. Also, inclusion criteria and exclusion criteria were identified separately. It was understood that there are novel therapeutic options against MDR <i>K. pneumoniae</i> infections, which include odilorhabdins, drug delivery systems, antibody drug conjugation treatments, nano-antibiotics, bacteriocins, probiotics, fecal transplant therapy, predatory bacteria, combined antibiotics, double-carbapenem therapy, synthetic lipopeptides, and phage therapy.</p>\",\"PeriodicalId\":18701,\"journal\":{\"name\":\"Microbial drug resistance\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbial drug resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10766294251375937\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10766294251375937","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

抗微生物药物耐药性(AMR)是世界上最重要的问题之一,发生在革兰氏阳性和革兰氏阴性细菌中。肺炎克雷伯菌(克雷伯菌)是一种革兰氏阴性菌,属于肠杆菌科,在医院感染的发展中也起着重要作用。抗菌素耐药性产生了三种形式,包括多重耐药、广泛耐药和泛耐药。现在,医生不能用典型的抗生素来拯救大多数耐多药肺炎克雷伯菌感染的患者,所以他们应该尝试其他有用的替代治疗方法。本综述的目的是寻找抗耐多药肺炎克雷伯菌感染的最新有效替代方法。我们以多重耐药肺炎克雷伯菌、AMR和替代治疗等关键词在PubMed、MEDLINE和谷歌Scholar上收集了部分文章,最终筛选出183篇。同时,分别确定纳入标准和排除标准。据了解,针对耐多药肺炎克雷伯菌感染有新的治疗选择,包括odilorhabdins、药物传递系统、抗体药物偶联治疗、纳米抗生素、细菌素、益生菌、粪便移植治疗、掠食性细菌、联合抗生素、双碳青霉烯类治疗、合成脂肽和噬菌体治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Overcoming Multi-Drug-Resistant Klebsiella pneumoniae Infections.

Antimicrobial resistance (AMR) is one of the most important concerns in the world, occurring for both Gram-positive and Gram-negative bacteria. Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative bacterium belonging to the family of Enterobacteriaceae and also plays an important role in development of nosocomial infections. Three forms have emerged as a result of AMR including multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant. Nowadays, physicians cannot save most of the patients that suffer from MDR K. pneumoniae infections by typical antibiotics, so they should try other useful alternative treatments. Our aim in this review study was to search about the latest useful alternative methods against MDR K. pneumoniae infections. We collected some articles from PubMed, MEDLINE, and Google Scholar by the keywords of multi-drug-resistant K. pneumoniae, AMR, and alternative treatments, where finally 183 articles were selected. Also, inclusion criteria and exclusion criteria were identified separately. It was understood that there are novel therapeutic options against MDR K. pneumoniae infections, which include odilorhabdins, drug delivery systems, antibody drug conjugation treatments, nano-antibiotics, bacteriocins, probiotics, fecal transplant therapy, predatory bacteria, combined antibiotics, double-carbapenem therapy, synthetic lipopeptides, and phage therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Microbial drug resistance
Microbial drug resistance 医学-传染病学
CiteScore
6.00
自引率
3.80%
发文量
118
审稿时长
6-12 weeks
期刊介绍: Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports. MDR coverage includes: Molecular biology of resistance mechanisms Virulence genes and disease Molecular epidemiology Drug design Infection control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信